Treatment of Chronic Rhinosinusitis with Unani Medicine Itrifal Zamani.

Clinical Validation of Unani Pharmacopoeal formulation Itrifal Zamani in Nazla Muzmin (Chronic Rhinosinusitis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015444

Enrollment

240

Registered

2018-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified Health Condition 2: null- Nazla Muzmin (Chronic Rhinosinusitis)

Interventions

Intervention1: Itrifal Zamani: Itrifal Zamani Semi solid Oral 7gm at bedtime to be taken with warm water for six weeks Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any in the age group of 18 to 60 years 2. Radiologically diagnosed Rhinosinusitis of more than12 weeks duration 3. SNOT Score > 11

Exclusion criteria

Exclusion criteria: 1. Rhinosinusitis /Sinusitis of 2. Deviated Nasal septum 3. Nasal polyps 4. Local pathology such as mucocele, cyst, antrochoanal polyp, facial trauma, radiation injury, or birth defect 5. Diabetes mellitus and any other illness requiring long term treatment 6. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
improvement in the sign and symptoms of Nazla Muzmin (Chronic Rhinosinusitis)Timepoint: six weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: six weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026